Sibel Health

Sibel Health is a telehealth startup offering wearable sensors, AI-enabled data analytics, and an online and mobile platform for clinician interface.  The company operates offices in California and South Korea and has partnerships with Fortune 500 companies and funding support from the US military, the National Institutes of Health, and the Bill & Melinda Gates Foundation.

In May 2023, Sibel received FDA 510(k) clearance for its ANNE One platform, a pediatric vital sign monitoring tool. The platform enables wireless monitoring of infants and neonate’s vital signs and is in two parts: 1) the Anne Limb, which measures skin and body temperature, and 2) the Anne Chest, which monitors skin temperature, heart and respiratory rates, and tracks both steps and falls of infants. The platform is paired with a mobile application for real-time access to data for families and caregivers. The platform previously received clearance in October 2021 for use in monitoring vital signs in adults in healthcare settings.       

Key customers and partnerships

In May 2023, Sibel announced it had partnered with Montreal Children's Hospital and McGill University to test its ANNE One platform to create the world’s first wireless Neonatal Intensive Care Unit (NICU). 

Sibel Health then partnered with Medidata in October 2023 to launch a monitoring tool, Discovery, which uses Sibel’s FDA-approved wearable sensors to monitor participants' vital signs.  Sibel additionally partnered with Medidata to integrate Sibel's Discovery platform into Medidata's cloud-based platform. Through the partnership, Medidata's platform would allow academic researchers, pharmaceutical, biotechnology, medical device, and diagnostics companies to access Sibel participants' data.

Funding and financials

In April 2024, Sibel Health received a USD 17.5 million grant from the Bill & Melinda Gates Foundation to make its FDA-cleared wireless monitoring solution, ANNE One, more accessible. The raised funds were set aside to enhance its platform with AI-driven clinical decision support and point-of-care ultrasound, supporting labor triage and continuous maternal health monitoring in low- and middle-income countries (LMICs). As of April 2024, the company had monitored more than 12,000 pregnancies in LMICs.